Coherus Oncology (NASDAQ:CHRS) Issues Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Coherus Oncology (NASDAQ:CHRS) released its quarterly earnings results on Wednesday. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.05, FiscalAI reports. Coherus Oncology had a negative net margin of 259.41% and a negative return on equity of 211.76%. The company had revenue of $14.31 million for the quarter, compared to the consensus estimate of $14.26 million.

Here are the key takeaways from Coherus Oncology’s conference call:

• LOQTORZI sales increased 15% quarter over quarter to $13.6 million, supported by the highest number of new patient starts since launch, lower discontinuations, and gradually improving treatment duration. Management reiterated its 2026 revenue outlook of $57 million to $62 million and expects average quarterly growth of 10% to 15%.
• Tagmokitug studies in head and neck cancer and colorectal cancer, along with the casdozokitug first-line HCC study, have completed enrollment. Early, immature data in PD-1-resistant head and neck cancer showed manageable safety and signs of activity, potentially enriched among HPV-positive patients and those with higher TIRI scores; a formal update is expected in October.
• Casdozokitug HCC data are expected in the fourth quarter, but the study remains relatively immature, with only about half of patients having received three scans. Management said it may not need to wait for overall-survival data to decide on a potential Phase III program, while emphasizing response durability, clinical benefit rate, ctDNA, and IL-27 biomarkers.
• Cash, cash equivalents, and investments declined to $105.3 million from $167 million in the prior quarter, primarily because of $39 million in transition-service-agreement obligations. The company said it remains funded through key 2026–2027 readouts, but the $37.5 million Q2 UDENYCA divestiture milestone was not achieved, subject to final buyer-result adjustments.
• Continuing-operations R&D and SG&A expenses fell year over year, and the company expects full-year 2026 operating expenses of $170 million to $175 million. Legacy biosimilar liabilities also declined substantially and are expected to be largely settled by year-end.

Coherus Oncology Price Performance

Shares of NASDAQ:CHRS traded up $0.12 on Friday, reaching $1.39. The company’s stock had a trading volume of 644,577 shares, compared to its average volume of 1,531,458. The company has a market cap of $213.64 million, a P/E ratio of -1.34 and a beta of 0.98. Coherus Oncology has a 52-week low of $0.81 and a 52-week high of $2.62. The company has a 50-day simple moving average of $1.46 and a 200 day simple moving average of $1.67. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.52 and a current ratio of 1.56.

Institutional Trading of Coherus Oncology

Several institutional investors and hedge funds have recently made changes to their positions in the business. Millennium Management LLC purchased a new stake in shares of Coherus Oncology in the 4th quarter worth approximately $938,000. Panagora Asset Management Inc. lifted its holdings in Coherus Oncology by 17.8% during the fourth quarter. Panagora Asset Management Inc. now owns 1,620,271 shares of the biotechnology company’s stock worth $2,301,000 after buying an additional 244,303 shares during the period. UBS Group AG boosted its position in Coherus Oncology by 38.5% during the 3rd quarter. UBS Group AG now owns 795,941 shares of the biotechnology company’s stock valued at $1,305,000 after acquiring an additional 221,410 shares in the last quarter. Acadian Asset Management LLC increased its holdings in shares of Coherus Oncology by 52,980.1% in the 1st quarter. Acadian Asset Management LLC now owns 196,927 shares of the biotechnology company’s stock valued at $158,000 after acquiring an additional 196,556 shares during the period. Finally, Bridgeway Capital Management LLC lifted its stake in shares of Coherus Oncology by 72.9% during the 4th quarter. Bridgeway Capital Management LLC now owns 441,000 shares of the biotechnology company’s stock worth $626,000 after purchasing an additional 186,000 shares during the last quarter. 72.82% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

CHRS has been the topic of several research analyst reports. Guggenheim started coverage on shares of Coherus Oncology in a research report on Monday, May 11th. They set a “buy” rating and a $12.00 price target on the stock. Weiss Ratings upgraded shares of Coherus Oncology from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 13th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $8.67.

Coherus Oncology Company Profile

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.